title: Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction.
abstract: Ruling out myocardial infarction in patients coming to the emergency room with chest pain is hindered by the lack of a specific early diagnostic marker. Less than 30 percent of patients admitted to coronary care units have infarction, resulting in substantial unnecessary expenditures. We developed a rapid assay of the subforms of creatine kinase MB (CK-MB) and prospectively analyzed its sensitivity and specificity in diagnosing myocardial infarction in the first six hours after the onset of chest pain.
  
  
  
  In 1110 consecutive patients who came to the emergency room with chest pain, blood samples were collected every 30 to 60 minutes until at least 6 hours after the onset of symptoms; in patients who were then admitted to the hospital, samples were collected every 4 hours for up to 48 hours. The samples were analyzed for CK-MB subforms, and the diagnosis of myocardial infarction was confirmed by conventional CK-MB analysis.
  
  
  
  Of the 1110 patients evaluated, 121 had myocardial infarction. The sensitivity of the assay of CK-MB subforms to detect myocardial infarction in the first six hours after the onset of symptoms was 95.7 per cent, as compared with only 48 percent for the conventional CK-MB assay; the specificity was 93.9 percent among patients hospitalized without myocardial infarction and 96.2 percent among those sent home. Among the patients with myocardial infarction, definitive results of the subform assay were available a mean (+/- SD) of 1.22 +/- 1.17 hours after their arrival in the emergency room.
  
  
  
  The assay of CK-MB subforms reliably detected myocardial infarction within the first six hours after the onset of symptoms, and its use could reduce admission to the coronary care unit by 50 to 70 percent, thereby reducing costs.
authors.affiliation: Department of Medicine, Christ Hospital, Cincinnati.
authors.forename: P R
authors.initials: PR
authors.lastname: Puleo
authors.forename: D
authors.initials: D
authors.lastname: Meyer
authors.forename: C
authors.initials: C
authors.lastname: Wathen
authors.forename: C B
authors.initials: CB
authors.lastname: Tawa
authors.forename: S
authors.initials: S
authors.lastname: Wheeler
authors.forename: R J
authors.initials: RJ
authors.lastname: Hamburg
authors.forename: N
authors.initials: N
authors.lastname: Ali
authors.forename: S D
authors.initials: SD
authors.lastname: Obermueller
authors.forename: J F
authors.initials: JF
authors.lastname: Triana
authors.forename: J L
authors.initials: JL
authors.lastname: Zimmerman
mesh_terms: D015415:Biomarkers / Q000097:blood; D016001:Confidence Intervals; D003325:Coronary Care Units / Q000191:economics / Q000706:statistics & numerical data; D003402:Creatine Kinase / Q000097:blood*; D003937:Diagnosis, Differential; D004562:Electrocardiography; D004586:Electrophoresis; D004630:Emergencies; D005260:Female; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis*; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D013997:Time Factors
chemical_list: D015415:Biomarkers; D007527:Isoenzymes; D003402:Creatine Kinase